Chief of department of pediatric | Capital Medical University | China
Dr. Yi Zhang is a dedicated clinician-researcher at Beijing Chao-Yang Hospital, Capital Medical University, recognized for impactful contributions at the intersection of infectious diseases, drug safety, and clinical therapeutics. With 35 peer-reviewed publications and over 465 citations, Dr. Zhang has established a strong scholarly footprint supported by extensive collaborations with more than 100 co-authors, reflecting an active role in multidisciplinary and multinational research networks. His recent work includes real-world evaluations of antiviral therapies, such as comparative analyses of Simnotrelvir-Ritonavir versus Nirmatrelvir-Ritonavir during the Omicron EG.5 surge, offering timely evidence to guide treatment strategies in evolving pandemic conditions. Dr. Zhang’s investigations into thrombotic microangiopathy linked to calcineurin inhibitors and thromboembolic or bleeding risks associated with angiogenesis inhibitors further highlight his commitment to advancing pharmacovigilance and patient safety in high-risk clinical populations. His broader research portfolio spans drug-related adverse events, therapeutic optimization, and outcomes research, contributing to improved clinical decision-making and enhanced healthcare quality. Dr. Zhang’s work holds clear societal relevance, particularly in informing evidence-based policies and strengthening clinical readiness for emerging infectious threats. Backed by a growing citation record and a solid h-index of 13, he continues to shape scientific discourse through rigorous methodology, collaborative engagement, and a focus on translating data into meaningful improvements in patient care.
1. Zhang, Y., Zhu, Y., Yang, H., Jiang, C., Chen, W., Zhang, H., Zhang, X., Wu, H., Li, J., & An, Z.-l. (2025). Efficacy and Safety of Simnotrelvir-Ritonavir Compared With Nirmatrelvir-Ritonavir in the Treatment of COVID-19: Real-World Evidence From a Retrospective Cohort Study During the Prevalence of the Omicron EG.5 Variant. Clinical Therapeutics. cited by 1.
2. Wang, Y., Ma, Z., An, Z., Zhang, Y., Feng, X., Yu, X. (2023, February). Risk of cutaneous adverse events in cancer patients treated with phosphatidylinositol-3-kinase inhibitors: A systematic review and meta-analysis of randomized controlled trials. Cancer Medicine. cited by 1.
3. Wang, Y., Ma, Z., Sun, X., Feng, X., An, Z., Zhang, Y. (2022, April). Interstitial lung disease in patients treated with Cyclin-Dependent Kinase 4/6 inhibitors: A systematic review and meta-analysis of randomized controlled trials. The Breast.
4. Ma, Z., Pei, J., Li, H., Sun, D., Zhang, Y., An, Z. (2022, August 05). Interstitial pneumonitis associated with EGFR/ALK tyrosine kinase inhibitors used in non–small cell lung cancer: an observational, retrospective, pharmacovigilance study. Expert Opinion on Drug Safety
5. Ma, Z., Sun, X., Yi, J., Li, H., An, Z., Zhang, Y. (2022, October). Risk of Thromboembolic Events in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Meta-analysis of Randomized Controlled Trials. Thrombosis and Haemostasis.
Dr. Yi Zhang’s work advances real-world evidence in infectious diseases and drug safety, offering crucial insights that improve clinical decision-making and patient outcomes. By evaluating treatment effectiveness and adverse drug events using large-scale surveillance data, the research supports safer therapies and strengthens global health systems. This vision drives innovation in evidence-based medicine and enhances preparedness for emerging health threats.